Meliodays Medical receives 800,000 euros for new therapy for menstrual pain

The Leipzig-based pharmaceutical start-up Meliodays Medical has successfully completed an oversubscribed pre-seed financing round totalling over 800,000 euros. The round was led by capacura GmbH and supported by FS Life Science Investment GmbH and several business angels from the healthcare sector. With MelioOne, the company is developing a locally effective, hormone-free treatment for menstrual cramps. The aim is to alleviate the pain directly in the uterus while avoiding the systemic side effects of conventional therapies. The technology is based on an established polymer that releases small amounts of painkillers in a targeted manner. CEO and co-founder Simone Sabbione sees the strong investor interest as a sign of the growing awareness that menstrual pain is a serious health problem. Up to 80 per cent of menstruating women suffer from it, and for around a third the pain has a significant impact on their daily lives. The fresh capital is being channelled into the further development of the product and the preparation of preclinical studies. Patent protection already exists in more than 150 countries. Meliodays Medical is also part of the Summer School for Diverse Startups, which promotes more diversity in the start-up scene.

Press release SpinLab Accelerator from 21 March 2025